Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 83.7 kDa respectively. The protein migrates as 16 kDa and 100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human PCSK9, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human VLDL R, His Tag (Cat. No. VLR-H5227) at 5 μg/mL (100 μL/well) can bind Human PCSK9, Fc Tag (Cat. No. PC9-H5256) with a linear range of 1-10 ng/mL (QC tested).
Immobilized Human PCSK9, Fc Tag (Cat. No. PC9-H5256) at 5 μg/mL (100 μL/well) can bind Biotinylated Human LDL R, His Tag, Avi Tag (Cat. No. LDR-H82E7) with a linear range of 0.04-0.625 μg/mL (Routinely tested).
Loaded Human PCSK9, Fc Tag (Cat. No. PC9-H5256) on Protein A Biosensor, can bind Human LDL R, His Tag (Cat. No. LDR-H5224) with an affinity constant of 12.7 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Inclisiran sodium | KJX-839; ALN-60212; PCSK9si; ALN-PCSsc; KJX839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio, 乐可为 | EU | Dyslipidemias; Hypercholesterolemia | Novartis Europharm Ltd | 2020-12-09 | Hypolipoproteinemias; Diabetes Mellitus; Hyperlipidemias; Hyperlipoproteinemia Type II; Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Coronary Disease; Acute Coronary Syndrome; Stroke; Plaque, Atherosclerotic; Coronary Artery Disease; Hypercholesterolemia; Renal Insufficiency; Myocardial Infarction; Diabetes Mellitus, Type 2; Carotid Artery Diseases; Atherosclerosis; Homozygous familial hypercholesterolemia | Details |
Ongericimab | JS-002 | Approved | Shanghai Junshi Biosciences Co Ltd | 君适达 | Mainland China | Hypercholesterolemia; Dyslipidemias | Shanghai Junshi Biosciences Co Ltd | 2024-10-09 | Hypertriglyceridemia; Atherosclerosis; Hypercholesterolemia; Neoplasms; Heterozygous familial hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
Ebronucimab | AK-102 | Approved | Zhongshan Akeso Biopharma Co Ltd, Yabao Us Pharmaceutical Co Ltd | 伊喜宁 | Mainland China | Hypercholesterolemia; Dyslipidemias | Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd | 2024-09-26 | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II | Details |
Recaticimab | SHR-1209 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾心安 | Mainland China | Hypercholesterolemia; Dyslipidemias | Guangdong Hengrui Pharmaceutical Co Ltd | 2025-01-08 | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II | Details |
Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | EU | Dyslipidemias; Hypercholesterolemia | Amgen Europe Bv | 2015-07-17 | Stroke; Heart Failure, Systolic; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Hyperlipidemias; Hyperlipoproteinemia Type II; Glioma; Rejection in heart transplantation; Cardiovascular Diseases; Coronary Disease; Dyslipidemias; Heterozygous familial hypercholesterolemia; HIV Infections; Acute Coronary Syndrome; Glioblastoma; Coronary Artery Disease; Sepsis; Hypercholesterolemia; ST Elevation Myocardial Infarction; Atherosclerosis; Diabetes Mellitus, Type 2; Myocardial Infarction; Homozygous familial hypercholesterolemia | Details |
Tafolecimab | IBI-306 | Approved | Innovent Biologics(Suzhou) Co Ltd | 信必乐 | Mainland China | Dyslipidemias; Hypercholesterolemia | Innovent Biologics(Suzhou) Co Ltd | 2023-08-15 | Homozygous familial hypercholesterolemia; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Dyslipidemias | Details |
Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 波立达, Praluent | United States | Hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2015-07-24 | Hemorrhage; Hyperlipidemias; Drinking Behavior; Cardiovascular Diseases; Ischemic Stroke; Vascular Diseases; Coronary Disease; Heterozygous familial hypercholesterolemia; Dyslipidemias; Angina Pectoris; Intracranial Arteriosclerosis; Stroke; Shock, Septic; Acute Coronary Syndrome; Hypercholesterolemia; Sepsis; Myocardial Infarction; Diabetes Mellitus, Type 2; ST Elevation Myocardial Infarction; Atherosclerosis; Homozygous familial hypercholesterolemia; Plaque, Atherosclerotic; Liver Diseases, Alcoholic; HIV Infections | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 3 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
AZD-0780 | AZD0780; AZD-0780 | Phase 3 Clinical | Dogma Therapeutics | Plaque, Atherosclerotic; Renal Insufficiency; Dyslipidemias; Hepatic Insufficiency; Cardiovascular Diseases | Details |
Enlicitide Decanoate | MK-0616 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Atherosclerosis; Renal Insufficiency; Hypercholesterolemia; Kidney Diseases; Cardiovascular Diseases; Hepatic Insufficiency; Arteriosclerosis; Hyperlipoproteinemia Type II | Details |
AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Kidney Failure, Chronic | Details |
CiVi-007 | CiVi-007; LNA-PCSK -9; LNA-PCSK9-GalNac | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hypercholesterolemia | Details |
CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
ATX-304 | O-304; ATX-304; O-304X | Phase 2 Clinical | Betagenon Ab | Mitochondrial Diseases; Diabetes Mellitus, Type 2; Peripheral Arterial Disease | Details |
MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
NNC0385-0434 | NNC0385-0434; NN-6435; NNC 0385 0434 | Phase 2 Clinical | Novo Nordisk A/S | Plaque, Atherosclerotic; Diabetes Mellitus, Type 2; Hypercholesterolemia; Cardiovascular Diseases; Arteriosclerosis; Renal Insufficiency, Chronic | Details |
PCSK9 Inhibitors therapy(Guangdong Provincial People'S Hospital) | Phase 2 Clinical | Guangdong Provincial People'S Hospital | Colorectal Neoplasms | Details | |
SYH-2053 | SYH2053; SYH-2053 | Phase 2 Clinical | CSPC Pharmaceutical Group Ltd | Hypercholesterolemia; Dyslipidemias; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
RBD-7022 | RBD7022; RBD-7022; SR043; SR-043; QLC-7401 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Hypercholesterolemia; Hyperlipidemias; Hyperlipidemia, Familial Combined | Details |
Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
DC-371739 | JYP-0739; DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Hypercholesterolemia; Dyslipidemias; Hyperlipidemias | Details |
Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | BIOCAD JSC | Cardiovascular Diseases | Details | |
ATH-04 | ATH-04; Affitope AT04A | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Plaque, Atherosclerotic; Hypercholesterolemia; Heterozygous familial hypercholesterolemia | Details |
SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Hypercholesterolemia; Dyslipidemias | Details |
VERVE-102 | VERVE-102 | Phase 1 Clinical | Verve Therapeutics Inc | Atherosclerosis; Heterozygous familial hypercholesterolemia; Coronary Disease | Details |
SGB-3403 | SGB-3403 | Phase 1 Clinical | Suzhou Sanegene Biopharmaceuticals Ltd | Atherosclerosis; Hypercholesterolemia; Heterozygous familial hypercholesterolemia; Cardiovascular Diseases; Hyperlipidemias | Details |
RN-0191 | RN0191 | Phase 1 Clinical | Darui Biomedical Technology (Shanghai) Co Ltd | Atherosclerosis; Hypercholesterolemia; Dyslipidemias | Details |
RP-910 | RP910; RP-910 | Phase 1 Clinical | Runjia (Shanghai) Pharmaceutical Technology Co Ltd | Metabolic Diseases; Hyperlipidemias | Details |
YOLT-101 | YOLT-101 | Phase 1 Clinical | Yoltech Therapeutics Co Ltd | Hyperlipoproteinemia Type II | Details |
JX-7002 | JX7002; JX-7002 | Phase 1 Clinical | Zhejiang Jingxin Pharmaceutical Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Metabolic Diseases; Inflammation | Details |
This web search service is supported by Google Inc.